One Way Holdings LLC lessened its position in Insulet Corporation (NASDAQ:PODD - Free Report) by 91.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,784 shares of the medical instruments supplier's stock after selling 48,334 shares during the period. One Way Holdings LLC's holdings in Insulet were worth $624,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Insulet during the third quarter valued at approximately $2,758,000. ProShare Advisors LLC lifted its position in Insulet by 6.0% in the 3rd quarter. ProShare Advisors LLC now owns 20,802 shares of the medical instruments supplier's stock valued at $2,714,000 after acquiring an additional 1,185 shares in the last quarter. Vise Technologies Inc. lifted its position in Insulet by 52.9% in the 3rd quarter. Vise Technologies Inc. now owns 5,503 shares of the medical instruments supplier's stock valued at $718,000 after acquiring an additional 1,903 shares in the last quarter. International Assets Investment Management LLC lifted its position in Insulet by 61,543.8% in the 3rd quarter. International Assets Investment Management LLC now owns 45,000 shares of the medical instruments supplier's stock valued at $5,871,000 after acquiring an additional 44,927 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in Insulet by 144.7% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,356 shares of the medical instruments supplier's stock valued at $3,308,000 after acquiring an additional 14,996 shares in the last quarter.
Wall Street Analyst Weigh In
Several analysts have commented on the company. Wells Fargo & Company downgraded Insulet from an "overweight" rating to an "equal weight" rating and cut their target price for the company from $255.00 to $144.00 in a research note on Wednesday, August 5th. UBS Group decreased their price target on Insulet from $174.00 to $150.00 and set a "neutral" rating for the company in a research note on Thursday, August 6th. Citigroup upped their price target on Insulet from $165.00 to $172.00 and gave the company a "neutral" rating in a report on Wednesday, July 8th. Sanford C. Bernstein dropped their price objective on Insulet from $200.00 to $175.00 and set an "outperform" rating on the stock in a research report on Thursday, August 6th. Finally, Stifel Nicolaus dropped their price objective on Insulet from $225.00 to $180.00 and set a "buy" rating on the stock in a research report on Thursday, August 6th. Thirteen analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $186.68.
Get Our Latest Research Report on Insulet
Insulet Stock Up 2.6%
Shares of Insulet stock opened at $153.61 on Tuesday. Insulet Corporation has a twelve month low of $126.40 and a twelve month high of $354.88. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. The company's 50 day moving average is $141.02 and its 200 day moving average is $179.25. The company has a market cap of $10.65 billion, a price-to-earnings ratio of 28.71, a price-to-earnings-growth ratio of 1.17 and a beta of 1.11.
Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping analysts' consensus estimates of $1.47 by $0.19. The business had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm's revenue was up 23.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. Research analysts anticipate that Insulet Corporation will post 6.51 EPS for the current year.
Insulet Company Profile
(
Free Report)
Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.
The company's primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.
Featured Stories
Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.